Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Three Upcoming Presentations Related to Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session
May 10, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Reports First Quarter 2021 Financial Results
May 06, 2021 16:00 ET | Cytokinetics, Incorporated
Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21 Company Plans to Submit NDA for Omecamtiv Mecarbil following Recent Meeting with FDA Results...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
May 06, 2021 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first site has been activated to enroll patients in REDWOOD-HCM OLE,...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Hold Annual Meeting of Stockholders
May 05, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 12,...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Cohort 3 of REDWOOD-HCM is Open to Enrollment
May 04, 2021 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 3 of REDWOOD-HCM (Randomized Evaluation of...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2021 it granted stock options to purchase an aggregate of...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Announce First Quarter Results on May 6, 2021
April 22, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 6, 2021 at 4:00...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting
April 12, 2021 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data related to the optimization of CK-3773274 (CK-274), including the...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 05, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting
April 02, 2021 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its...